GSMA
6.6.2018 10:02:09 CEST | Business Wire | Press release
As part of its role within the W20 (Women 20) group1 , the GSMA has backed a series of recommendations to promote digital inclusion for women to be presented to the G20 member states later this year. The GSMA is Topic Chair of the Digital Inclusion theme within the W20, which is advising the G20 on issues around gender equality and the economic empowerment of women, supporting the Sustainable Development Goals (SDGs), particularly SDG #5 (Gender Equality).
“The GSMA has been privileged to help shape the W20 recommendations, which will provide an actionable roadmap for the G20 nations to drive gender equality policies around the world,” said Mats Granryd, Director General of the GSMA. “These recommendations underline the importance of closing the digital gender gap by removing barriers to access and use, and promoting policies that encourage the digital inclusion of women. We believe this approach will ensure women and girls play a major role in shaping our future digital economies.”
“Ensuring that women are digitally included brings significant benefits for them and for their communities and economies”, added Susana Balbo, Chair of the W20.
At a W20 roundtable in Paris last week, the GSMA chaired the debate between the W20 delegates to set the Digital Inclusion recommendations. There are four agreed recommendations that call on G20 member states to:
1) Collect, track and analyse data on women’s access to and use of digital technologies and on the presence of women in STEM-related courses, careers and in leadership positions;
2) Develop holistic policies that focus on the barriers to women’s access to and use of digital technologies including accessibility, affordability, safety and security, digital skills and availability of relevant content and services;
3) Promote initiatives that drive equal participation of women and girls in STEM studies and digital-intensive work to ensure that women participate and lead in the design, development and governance of digital technologies, as well as entrepreneurs in the digital sector;
4) Ensure that all analyses of the future of work, including education needs and demands for new skills, are performed with a view to gender balance, social protection and job quality.
These recommendations feed into what will be presented at the G20 Argentina 2018 summit taking place in Buenos Aires, 30 November – 1 December 2018, where the G20 governments will be asked to make concrete commitments on each issue.
Mobile Industry Supporting Digital Inclusion for Women
The
GSMA is committed to supporting increased digital and financial
inclusion for women, reflecting the fact that mobile is the primary way
for people to access the internet in many parts of the world. However,
according to the latest GSMA research2
, women in low- and
middle-income countries are 26 percent less likely than men to use
mobile internet.
As part of the GSMA’s Connected Women initiative, 36 mobile operators across Africa, Asia and Latin America have made 51 formal commitments to reduce the gender gap in their mobile money or mobile internet customer base, driving an effort to accelerate digital and financial inclusion for women. To date, the Connected Women programme and its mobile operator partners have delivered life-enhancing services to more than 22 million women.
As well as the Connected Women programme and its participation in W20 , the GSMA also supports efforts to accelerate digital and financial inclusion for women via its participation in W20 ; the EQUALS initiative; the GSMA Connected Women programme; Women4Tech ; the WeCare initiative in Latin America; and the #BetterFuture campaign.
-ENDS-
About the GSMA
The GSMA represents the interests of mobile
operators worldwide, uniting nearly 800 operators with more than 300
companies in the broader mobile ecosystem, including handset and device
makers, software companies, equipment providers and internet companies,
as well as organisations in adjacent industry sectors. The GSMA also
produces industry-leading events such as Mobile World Congress, Mobile
World Congress Shanghai, Mobile World Congress Americas and the Mobile
360 Series of conferences.
For more information, please visit the GSMA corporate website at www.gsma.com . Follow the GSMA on Twitter: @GSMA .
________________________
1
The W20 is one of seven
independent engagement groups comprised of civil society organisations
from the G20 member counties. The engagement groups convene in tandem
with the G20 and ensure that the position of civil society on important
issues is taken on board by the G20 leaders. For more information see http://w20argentina.com
2
https://www.gsma.com/mobilefordevelopment/programmes/connected-women/the-mobile-gender-gap-report-2018
View source version on businesswire.com: https://www.businesswire.com/news/home/20180606005078/en/
Contact:
For the GSMA
Beau Bass
+44 79 7662 4962
beau.bass@webershandwick.com
or
GSMA
Press Office
pressoffice@gsma.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 11:48:00 CEST | Press release
Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
